News

The PDC platform has showed highly selective cancer targeting both preclinically in more than 60 in vivo cancer models, and subsequently confirmed clinically in over ten cancer types.

Currently, SER-109 is being examined as a new therapeutic modality to treat recurrent CDI by correcting a dysbiosis of the human microbiome, which is an underlying cause of

In July, ixazomib was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The MAA was based on the results of the first

Eteplirsen is designed to address the underlying cause of DMD by allowing the production of a functional dystrophin protein. The company said that data from clinical trials of

Ofatumumab, a fully human monoclonal antibody currently being designed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications, targets CD20 and is administered by subcutaneous injection. Previously,

Paliperidone palmitate once-monthly is an atypical long-acting injection to treat schizophrenia and is now approved in more than 80 countries, while the drug is marketed as Xeplion in

BTA585 is an orally bioavailable compound being developed to treat respiratory syncytial virus (RSV) infections in children, the elderly and immunocompromised patients. The Phase I SAD trial has

A six-month review period has been assigned for the sBLA and the Prescription Drug User Fee Act (PDUFA) date is expected to be in the first quarter of

Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. As part of the deal, PharmaMar will receive an upfront payment, royalties